Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19
Medical Principles and Practice · 2025
DOI: 10.1159/000543773 ↗At a glance
Randomisierte kontrollierte Studie in Medical Principles and Practice, 2025. Written by Dorina Esendagli and 23 co-authors. Institution: Department of Chest Diseases, Faculty of Medicine, Başkent University, Ankara, Turkey. Major MEDLINE topics: COVID-19 Drug Treatment. Cited 7 times so far (Crossref); 21 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Objective
We are still in search of new therapeutic options for COVID-19 to prevent new infections, enable fast recovery, and reduce the long-lasting symptoms or sequelae. This study aimed to investigate the short- and long-term effects of inhaled aviptadil on hospitalized, adult COVID-19 patients.
Methods
A multicenter, prospective, placebo-controlled, comparative, randomized, double-blind clinical trial was conducted. Patients were randomized 1:1 to either inhaled aviptadil or placebo, in addition to the standard care. The primary endpoint is the time from hospitalization to discharge within 30 days of treatment. The secondary endpoints are clinical and radiological score improvements.
Results
The study involved 80 patients enrolled from 9 clinical centers. The mean age was 55.8 ± 18.5 years, and 27 of them (33.8%) were female. The average time to discharge was 7.8 ± 4.0 days in aviptadil group and 10 ± 5.0 days in placebo (p = 0.049). Modified Borg scales were not statistically different on day 3 (p = 0.090), but significantly lower in the aviptadil group on day 7 (p = 0.033). The CT lung damage score was not different on day 1 for both groups (p = 0.962); improvement on day 28 was significantly greater in the aviptadil group (p = 0.028). The death rate was also lower in the aviptadil group (5.1%) when compared to the placebo (12.2%). There was no drop-out due to side effects.
Conclusion
Study shows that inhaled aviptadil is well tolerated and can be used as a supplementary intervention to fasten the recovery of respiratory manifestations in hospitalized patients for COVID-19 pneumonia.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Chest Diseases, Faculty of Medicine, Başkent University, Ankara, Turkey.
- Department of Infectious Diseases and Clinical Microbiology, Başkent University Ankara, Ankara, Turkey.
- Department of Infectious Diseases and Clinical Microbiology, Kocaeli University, İzmit, Turkey.
- Department of Infectious Diseases and Clinical Microbiology, Karadeniz Technical University, Trabzon, Turkey.
- Department of Chest Diseases, Vakfıkebir State Hospital, Trabzon, Turkey.
- Department of Infectious Diseases and Clinical Microbiology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, İstanbul, Turkey.
Cite
APA
Esendagli, D., Sarı, N., Akhan, S., Arslan, S., Doğan Öntaş, İ. A., Yılmaz, G., Aksoy, F., Kant, A., Yaşar, K. K., Ünlü, E. C., Akıllı, I. K., Çelen, M. K., Mermutluoğlu, Ç., Dayan, S., Kara, E., Durhan, G., Ünal, S., Demirkol, B., Arafat, L., …, & İnkaya, A. Ç. (2025). Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19. Medical Principles and Practice. https://doi.org/10.1159/000543773
Vancouver
Esendagli D, Sarı N, Akhan S, Arslan S, Doğan Öntaş İA, Yılmaz G, et al. Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19. Medical Principles and Practice. 2025. doi:10.1159/000543773
BibTeX
@article{Esendagli2025,
author = {Esendagli, Dorina and Sarı, Nuran and Akhan, Sıla and Arslan, Sonay and Doğan Öntaş, İrem Asena and Yılmaz, Gürdal and Aksoy, Firdevs and Kant, Aydın and Yaşar, Kadriye Kart and Ünlü, Esra Canbolat and Akıllı, Işıl Kibar and Çelen, Mustafa Kemal and Mermutluoğlu, Çiğdem and Dayan, Saim and Kara, Emre and Durhan, Gamze and Ünal, Serhat and Demirkol, Barış and Arafat, Levent and Çetinkaya, Erdoğan and Çörtük, Mustafa and Durmuş Koçak, Nagihan and Parmaksız, Elif Torun and İnkaya, Ahmet Çağkan},
title = {Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19},
journal = {Medical Principles and Practice},
year = {2025},
doi = {10.1159/000543773}
}
EUVIMED